GRPH - Graphite Bio, Inc.
After hours:
| Previous Close | 2.8400 |
| Open | 2.8200 |
| Bid | 2.8800 x 1100 |
| Ask | 2.9400 x 1800 |
| Day's Range | 2.7400 - 2.9300 |
| 52 Week Range | 1.5900 - 4.4800 |
| Volume | |
| Avg. Volume | 146,382 |
| Market Cap | 169.66M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%
Key Insights Significant control over Graphite Bio by private equity firms implies that the general public has more...
- Zacks
Should You Buy Graphite Bio (GRPH) Ahead of Earnings?
Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Simply Wall St.
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Zacks
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Reuters
Graphite Bio pauses early-stage blood disease therapy trial
Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the first patient dosed, sending its shares down nearly 48% in after hours trading. After being given Graphite's therapy, nula-cel, the patient showed prolonged low blood cell counts and required continued transfusion of blood, which the company believes is likely related to its treatment. Graphite said it has reported the incident to the U.S. Food and Drug Administration (FDA), and the patient has shown no evidence of blood cancer.
- Simply Wall St.
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
